Implantation of the Ventura interatrial shunt, while safe, does not improve clinical outcomes or prognosis in patients with HF and preserved LVEF.

R3 Vascular announced today that the FDA granted investigational device exemption (IDE) to evaluate its Magnitude drug-eluting bioresorbable scaffold. Mountain View, California-based R3 Vascular ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Consultant ...

Adona Medical is developing what it describes as a novel interatrial shunt with integrated bi-atrial pressure monitoring. [Image courtesy of Adona Medical. Shifamed‘s Adona Medical announced the ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

The Adona implant represents the next-generation of shunt technology, designed for dynamic interatrial flow that can be modified based on patient-specific hemodynamic needs," said Dr. Singh ...

The initial cases of Adona Medical's adjustable interatrial shunt for heart failure were conducted in the Republic of Georgia led by Dr. George Khabeishvili and supported by US experts Dr.

The Israeli company has now become part of Johnson & Johnson MedTech. V-Wave’s proprietary, minimally invasive Ventura Interatrial Shunt (IAS) is designed to treat patients with heart failure. The ...